Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Immedica Pharma clinical trials
The registry lists 30 studies whose lead sponsor is Immedica Pharma or one of 1 company grouped under it. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 24, 2026.
Keep track of what changes. Save the Immedica Pharma studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Immedica Pharma.
- Marinus Pharmaceuticals22 studies →Acquired — became part of Immedica Pharma, Feb 7, 2025 · source ↗
Something wrong?
- Immedica Pharma AB7 studiesSame company
Something wrong?
- Immedica Pharma US Inc1 studySame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 30 of 30.
- Double-blind, Randomized, Placebo-controlled Trial of Ganaxolone in CDKL5 Deficiency Patients 6 Months to Less Than 2 Years OldNot yet recruitingNCT05249556Phase 3
Sponsor listed in the registry: Immedica Pharma AB
- Evaluation of the Safety of Loargys Arginine Test System in Loargys-treated PatientsRecruitingNCT07573059Not applicable
Sponsor listed in the registry: Immedica Pharma US Inc
- A Study of AEB1102 (Pegzilarginase) in Patients With Arginase 1 DeficiencyCompletedNCT03378531Phase 2
Sponsor listed in the registry: Immedica Pharma AB
- Efficacy and Safety of Pegzilarginase in Patients With Arginase 1 DeficiencyCompletedNCT03921541Phase 3
Sponsor listed in the registry: Immedica Pharma AB
- A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDSCompletedNCT02732184Phase 1
Sponsor listed in the registry: Immedica Pharma AB
- A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid TumorsCompletedNCT02561234Phase 1
Sponsor listed in the registry: Immedica Pharma AB
- Long-term Safety Study of Chronocort in the Treatment of Participants With Congenital Adrenal HyperplasiaCompletedNCT05299554Phase 3
Sponsor listed in the registry: Immedica Pharma AB
- Pegzilarginase in Subjects <24 Months Old With Arginase 1 DeficiencyCompletedNCT06582524Phase 3
Sponsor listed in the registry: Immedica Pharma AB
- Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related EpilepsyTerminatedNCT05604170Phase 3
Sponsor listed in the registry: Marinus Pharmaceuticals · First submitted before Marinus Pharmaceuticals became part of Immedica Pharma
- Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related EpilepsyCompletedNCT05323734Phase 3
Sponsor listed in the registry: Marinus Pharmaceuticals · First submitted before Marinus Pharmaceuticals became part of Immedica Pharma
- Randomized Therapy In Status EpilepticusCompletedNCT04391569Phase 3
Sponsor listed in the registry: Marinus Pharmaceuticals · First submitted before Marinus Pharmaceuticals became part of Immedica Pharma
- Open-label Extension to Protocol 1042-0500TerminatedNCT00442104Phase 2
Sponsor listed in the registry: Marinus Pharmaceuticals · First submitted before Marinus Pharmaceuticals became part of Immedica Pharma
- To Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ganaxolone Added to Standard of Care in Refractory Status Epilepticus (RSE)WithdrawnNCT05814523Phase 3
Sponsor listed in the registry: Marinus Pharmaceuticals · First submitted before Marinus Pharmaceuticals became part of Immedica Pharma
- Safety and Efficacy Study of IV Ganaxolone as Adjuvant Therapy for Established Status Epilepticus (ESE)WithdrawnNCT05757544Phase 2
Sponsor listed in the registry: Marinus Pharmaceuticals · First submitted before Marinus Pharmaceuticals became part of Immedica Pharma
- Ganaxolone Expanded Access Program Compassionate UseNo longer availableNCT04678479
Sponsor listed in the registry: Marinus Pharmaceuticals · First submitted before Marinus Pharmaceuticals became part of Immedica Pharma
- A Clinical Trial of Oral Ganaxolone in Women With Postpartum DepressionCompletedNCT03460756Phase 2
Sponsor listed in the registry: Marinus Pharmaceuticals · First submitted before Marinus Pharmaceuticals became part of Immedica Pharma
- A Clinical Trial of Intravenous (IV) Ganaxolone in Women With Postpartum DepressionCompletedNCT03228394Phase 2
Sponsor listed in the registry: Marinus Pharmaceuticals · First submitted before Marinus Pharmaceuticals became part of Immedica Pharma
- A Two-year Open-label Extension Study of Ganaxolone in Patients With Drug-resistant Partial-onset SeizuresTerminatedNCT02519439Phase 3
Sponsor listed in the registry: Marinus Pharmaceuticals · First submitted before Marinus Pharmaceuticals became part of Immedica Pharma
- Study of Adjunctive Ganaxolone Treatment in Female Children With Protocadherin 19 (PCDH19)-Related Epilepsy (Violet Study)CompletedNCT03865732Phase 2
Sponsor listed in the registry: Marinus Pharmaceuticals · First submitted before Marinus Pharmaceuticals became part of Immedica Pharma
- A Randomized, Controlled Trial of Ganaxolone in Patients With Infantile SpasmsCompletedNCT00441896Phase 2
Sponsor listed in the registry: Marinus Pharmaceuticals · First submitted before Marinus Pharmaceuticals became part of Immedica Pharma
- Study of Adjunctive Ganaxolone Treatment in Children and Young Adults With CDKL5 Deficiency DisorderCompletedNCT03572933Phase 3
Sponsor listed in the registry: Marinus Pharmaceuticals · First submitted before Marinus Pharmaceuticals became part of Immedica Pharma
- Ganaxolone Treatment in Children With Fragile X SyndromeCompletedNCT01725152Phase 2
Sponsor listed in the registry: Marinus Pharmaceuticals · First submitted before Marinus Pharmaceuticals became part of Immedica Pharma
- Adjunctive Ganaxolone Treatment (Part A) in TSC Followed by Long-term Treatment (Part B)CompletedNCT04285346Phase 2
Sponsor listed in the registry: Marinus Pharmaceuticals · First submitted before Marinus Pharmaceuticals became part of Immedica Pharma
- Open-Label PoC Trial of Ganaxolone in Children With PCDH19 Female Pediatric Epilepsy and Other Rare Genetic EpilepsiesCompletedNCT02358538Phase 2
Sponsor listed in the registry: Marinus Pharmaceuticals · First submitted before Marinus Pharmaceuticals became part of Immedica Pharma
- A Randomized, Controlled Trial of Ganaxolone in Adult Uncontrolled Partial-Onset SeizuresCompletedNCT00465517Phase 2
Sponsor listed in the registry: Marinus Pharmaceuticals · First submitted before Marinus Pharmaceuticals became part of Immedica Pharma
- Intravenous Ganaxolone as Adjunctive Therapy to Treat Subjects With Status EpilepticusCompletedNCT03350035Phase 2
Sponsor listed in the registry: Marinus Pharmaceuticals · First submitted before Marinus Pharmaceuticals became part of Immedica Pharma
- Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label ExtensionCompletedNCT01963208Phase 3
Sponsor listed in the registry: Marinus Pharmaceuticals · First submitted before Marinus Pharmaceuticals became part of Immedica Pharma
- Open-label Extension to Protocol 1042-0600CompletedNCT00512317Phase 2
Sponsor listed in the registry: Marinus Pharmaceuticals · First submitted before Marinus Pharmaceuticals became part of Immedica Pharma
- Ganaxolone in Posttraumatic Stress Disorder (PTSD)CompletedNCT01339689Phase 2
Sponsor listed in the registry: Marinus Pharmaceuticals · First submitted before Marinus Pharmaceuticals became part of Immedica Pharma
- A Treatment Use Protocol for Subjects Continuing on From the Open-label Extension 0601CompletedNCT01002820Phase 2
Sponsor listed in the registry: Marinus Pharmaceuticals · First submitted before Marinus Pharmaceuticals became part of Immedica Pharma